NEUP · Neuphoria Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Lynx1 Capital Management LP 10% Owner | ▲ Buy | Open Market | 875,328 Shares held | 10/21/2025 | View profile |
Transaction History
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 639,110 | $3.3M | 10/21/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Scancell Secures Debt Financing for Phase 3 Trials
Scancell, a subsidiary of Neuphoria Therapeutics, has completed up to US$25 million in debt financing. This funding provides additional options to support the Phase 3 development of iSCIB1+. The capital helps finance clinical trials, which is a key step in the company's development pipeline.
Scancell Secures Debt Financing for Phase 3 Trials. Scancell, a subsidiary of Neuphoria Therapeutics, has completed up to US$25 million in debt financing. This funding provides additional options to support the Phase 3 development of iSCIB1+. The capital helps finance clinical trials, which is a key step in the company's development pipeline.